Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-327-1
CAS number: 119-47-1
No studies on toxicokinetics of
6,6’-di-tert-butyl-2,2’-methylendi-p-cresol (DBMC) are available.
However, considering the toxicokinetic profile of structural analogues
and taking into account the experiences with DBMC in acute and repeated
dose toxicity studies, a characterization of DBMC toxicokinetics can be
DBMC is a solid powder with a low vapour pressure (calculated to be <
0.1hPa, 20°C) under normal ambient conditions, therefore inhalation
exposure to the vapour might be negligible.
DBMC is practically insoluble in water (0.007 mg/l at 20°C). However,
the molecular mass of 342 g/mol and the n-octanol/water coefficient (log
Pow of 6.25) suggest intestinal absorption subsequent to oral ingestion.
This assumption is confirmed by data from acute oral toxicity studies
and repeated dose toxicity studies. However, acute toxicity is low
because LD50 values are high (greater than or even to 5000 mg/kg bw,
Takagi 1994, American Cyanamid Company 1965, Hagan 1952, Garlanda 1962,
Stasenkova 1977. In addition, studies with repeated oral dosing of rats
indicating bioavailability of the compound by showing dose related toxic
effects at doses > 12.7 mg/kg bw, predominantly in the testes and liver.
Available repeated dose toxicity studies are a subacute toxicity study
with rats (MHWJ 1996), subchronic toxicity studies with rats (Bayer AG
1982, Takagi 1994) or dogs (American Cyanamid Company 1965), a chronic
feeding study with rats (Takagi 1994) and a reproduction toxicity
screening study (MHWJ 1999). The determined NOAELs in these studies were
in the order of 10 mg/kg bw/day.
DBMC showed a very low skin and eye irritating potential in rabbits
(Raschig AG 1995). In addition, in a modified Local Lymph node Assay
(LLNA) neither a non-specific (irritant) nor a specific immune
stimulating (sensitizing) potential of the test substance was indicated
in NMRI mice (Bayer Schering Pharma AG 2010). Furthermore, the dermal
LD50 value of > 10000 mg/kg and the absence of significant signs of
systemic toxicity when dosed once at 10000 mg/kg bw reveal a very low
toxic potential of DMBC after dermal exposure.
The formation of DNA reactive metabolites is unlikely, since in vitro
and in vivo mutagenicity tests (Ames assay MHWJ 1996, in vitro
chromosome aberration assay MHWJ 1996, in vivo micronucleus assay OECD
SIDS 2003) show negative results. In addition, the cytotoxicity of the
test substance DMBC was reduced in the presence of the rat liver
microsomal fraction. This suggests that detoxification of DBMC occurs as
a result of liver enzyme activity or even as a detoxification by
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Esta web utiliza cookies para mejorar su experiencia de navegación en nuestros sitios web.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again